Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. Its product range includes dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under brands such as Spinach, Lord Jones, Lit, and Peace Naturals. The company is headquartered in Stayner, Canada.
Cronos Group Swings to $35.7 Million Profit as Israel Opens Dumping Probe
Cronos Group reported second quarter net income of $35.7 million, compared with a $38.5 million loss a year earlier, as net revenue climbed 58% year over year to $53.0 million. Gross profit nearly doubled, up 96% to $28.5 million, gross margin expanded 11 percentage points to 54%, and adjusted EBITDA jumped to $13.1 million from $1.7 million. The company disclosed that on August 5 Israeli regulators notified it of a new investigation into alleged dumping of Canadian cannabis imports, a threat aimed at the market driving most of its growth; Cronos disputes the allegations but cannot predict the outcome. Cronos Israel logged its tenth consecutive quarter of record net revenue, up 60% year over year, while international net revenue outside Canada and Israel also hit a record, growing 88% on strong German flower demand. The company repurchased 12.3 million shares in the first half of 2026 while holding $827 million in cash, deposits and short-term investments, though cash and cash equivalents alone fell 41% to $467 million and capital expenditures dropped 54% to $1.8 million.
CRON · Capital · Positive Cronos swung to $35.7M net income with revenue up 58%, gross margin expanding to 54%, and adjusted EBITDA jumping to $13.1M.
CRON · Regulation · Negative Israeli regulators opened a dumping investigation into Canadian cannabis imports, threatening the market driving most of Cronos's growth.
Cronos Reports Record Q2 Revenue, Gross Profit, and Adjusted EBITDA
Cronos Group reported record second-quarter 2026 results, with consolidated net revenue of $53 million, up 58% year-over-year, gross profit of $28.5 million, up 96%, and adjusted EBITDA of $13.1 million, an improvement of $11.4 million. The company attributed the growth to higher cannabis flower sales in Israel, Canada, and Germany, as well as higher extract sales in Canada, with gross margin benefiting from favorable mix and seasonally better growing conditions. Cronos also announced that the Israeli Trade Levies Commissioner has opened a new investigation into alleged dumping of medical cannabis imports from Canada, which the company disputes and says it will cooperate with fully. The company ended the quarter with $827 million in cash, cash equivalents, short-term investments, and non-current interest-bearing deposits, and expects to close its acquisition of CanAdelaar in the Netherlands in the second half of 2026.
CRON · Capital · Positive Record Q2 revenue, gross profit, and adjusted EBITDA beat expectations.
CRON · Regulation · Negative Israeli Trade Levies Commissioner opened a dumping investigation into medical cannabis imports from Canada, which Cronos disputes.
CanAdelaar · Capital · Positive Cronos expects to close acquisition of CanAdelaar in H2 2026, indicating growth.
Cronos Group sets August 6, 2026 for second quarter earnings call
Cronos Group Inc. will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. Eastern Time. Senior management will discuss the company’s financial results and take questions from the investment community after prepared remarks. Participants can register for the call or webcast online at the company’s investor relations events page, and the webcast will be archived for replay on the company’s website.
Cronos Appoints ATB Cormark as Broker for Share Repurchases in Canada
Cronos Group announced it has appointed ATB Capital Markets Corp., doing business as ATB Cormark, to act as its broker for share repurchases over the facilities of the TSX or other alternative Canadian trading systems, replacing Virtu Canada Corp. The appointment is made under the company's previously announced share repurchase program. Cronos is an innovative global cannabis company with a diverse international brand portfolio including Spinach, PEACE NATURALS, LIT and Lord Jones.
Cronos Group Q1 Revenue Jumps 40% but Zacks Rates Stock a Sell
Cronos Group reported first-quarter 2026 net revenue of $45.2 million, a 40% year-over-year increase driven by higher cannabis flower sales in Israel, Canada, and other international markets. Gross profit rose 39% to $19.2 million, while its Canadian brands posted 18% retail sales growth, far outpacing the industry's 2% gain. Despite the strong quarter, Zacks Investment Research assigns Cronos a Zacks Rank of 4, or Sell, citing intense competition from peers such as Aurora Cannabis and Tilray Brands and caution about the pace at which strategic initiatives will translate into sustained earnings growth. The company's shares have risen more than 2% year to date, compared with a nearly 7% decline for the industry.
CRON · Demand · Positive Cronos reported 40% revenue growth driven by higher cannabis flower sales in Israel, Canada, and other international markets, and its Canadian brands outpaced industry growth.
ACB · Competition · Negative Article mentions Aurora Cannabis as a competitor in a market where Cronos is gaining share, implying competitive pressure on Aurora.
TLRY · Competition · Negative Article mentions Tilray as a competitor in a market where Cronos is gaining share, implying competitive pressure on Tilray.
Cronos Group shareholders elect all seven directors at 2026 annual meeting
Cronos Group Inc. announced that shareholders elected all seven director nominees at its annual meeting held on June 18, 2026, with each receiving over 93.6% of votes cast in favor. Shareholders holding 271,828,759 common shares, representing 72.24% of outstanding shares, voted in person or by proxy. An advisory resolution on executive compensation was approved with 99.09% support, and shareholders voted in favor of holding such advisory votes annually. The appointment of Davidson & Company LLP as independent auditor for fiscal 2026 was also approved.
Cronos Group Expands Share Buyback to US$50 Million Across US and Canadian Exchanges
Cronos Group has expanded its share repurchase program after receiving Toronto Stock Exchange approval, allowing the company to buy back up to US$50,000,000 of common shares on both US and Canadian exchanges through May 13, 2027. The cross-listing expansion signals management's capital allocation priorities and view of intrinsic value. The company recently reported first-quarter 2026 revenue of US$45.21 million and net income of US$13.75 million. While the buyback supports the near-term narrative of returning capital, it also raises questions about financial flexibility amid ongoing cash outflows and capital spending.
CRON · Capital · Positive Cronos Group expanded its share buyback program to US$50 million, signaling capital allocation priorities and intrinsic value view.
USA
Canada
Israel
Germany